Rover Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Rover Diagnostics's estimated annual revenue is currently $2M per year.
- Rover Diagnostics's estimated revenue per employee is $155,000
Employee Data
- Rover Diagnostics has 13 Employees.
- Rover Diagnostics grew their employee count by 8% last year.
Rover Diagnostics's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Commercialization | Reveal Email/Phone |
2 | VP Engineering and Development | Reveal Email/Phone |
3 | Director Administration | Reveal Email/Phone |
4 | Instrument Engineer | Reveal Email/Phone |
5 | Laboratory Technician | Reveal Email/Phone |
6 | Mechanical Engineer | Reveal Email/Phone |
Rover Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Rover Diagnostics?
Rover Diagnostics was founded in 2018 by Samuel Sia and Mark Fasciano in collaboration with Columbia University. Based in New York City, Rover’s primary mission is to help meet the urgent global need for a cost-effective, highly sensitive, mass-produced point-of-care COVID-19 instrument and test kit system. Rover is a participant in the NIH RADx program to accelerate availability and capacity for COVID testing.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.2M | 14 | 17% | N/A |
#2 | $3.5M | 14 | -22% | N/A |
#3 | $1.2M | 14 | 17% | N/A |
#4 | $1.3M | 15 | 200% | N/A |
#5 | $2.3M | 15 | -62% | N/A |